Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 11/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.57 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055422 | 0.85 | ALPL (0.67) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL6985862 | 0.82 | ALDH1A1 (0.78) | ALPLALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL3061828 | 0.81 | ALPL (0.62) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL3825952 | 0.81 | PPARG (0.65) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL27963947 | 0.81 | ALPL (0.61) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL3448350 | 0.80 | ALPL (0.67) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL7719310 | 0.80 | ALPL (0.60) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL3071884 | 0.80 | SLC40A1 (0.55) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL3064501 | 0.79 | SLC40A1 (0.54) | ALPLALDH1A1KDM4EKMT2ARAB9A | |
| SCHEMBL13539328 | 0.79 | KDM4E (0.62) | ALPLALDH1A1KDM4EKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-2291372-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | Burnham Institute for Medical Research (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009143150-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-11-26 | — | — | WO | disclosed |
| US-6602883-B1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-6387926-B1 | ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-14 | — | — | US | disclosed |
| EP-0994856-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| CN-1261880-A | Inhibitors of farnesyl protein transferase | BRISTOL MYERS SQUIBB CO (US) | 2000-08-02 | — | — | CN | disclosed |
| EP-0994856-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001434-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | ALPI, SI, FABP2 | ALPL 5/4885ALDH1A1 2169/4885KDM4E 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.